1. A35 NEUTROPHIL ELASTASE PROTEOLYTIC ACTIVITY DRIVES A NOVEL PRO-RESOLUTION CELL MIGRATION PHENOTYPE. (15th March 2019) Authors: Gordon, M; Dufour, A; MacNaughton, W Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 2(2019)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. N22 Audit into initial response to vedolizumab infusions for IBD. (25th January 2019) Authors: Lloyd-Ford, G; Gordon, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A95 INFLAMMATORY PROTEASES DRIVE A MIGRATORY INTESTINAL EPITHELIAL PHENOTYPE THROUGH THE GENERATION OF BIOACTIVE PEPTIDE FRAGMENTS OF E-CADHERIN. (1st March 2018) Authors: Gordon, M; Chauvin, A; Boisvert, F; MacNaughton, W Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A211 PROTEOLYTIC CLEAVAGE OF E-CADHERIN BY INFLAMMATORY PROTEASES PRODUCES BIOACTIVE PEPTIDES THAT MODIFY EPITHELIAL FUNCTION. (1st March 2018) Authors: Gordon, M; MacNaughton, W Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1154PA phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors. (23rd October 2018) Authors: Denlinger, C S; Infante, J R; Aljumaily, R; Naing, A; Chintakuntlawar, A; Rizvi, N A; Ross, H; Gordon, M; Kumar, R; Ma, M; Yan, L; Vicini, P; Standifer, N; Cann, J; Perera, A; Durham, N; Krishnan, S; Balmanoukian, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 567PResults of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer. (23rd October 2018) Authors: Lenz, H-J; Park, H; Shah, M A; Berlin, J D; Bruetman, D; Chaves, J; Gordon, M; Patel, R; Starodub, A; Liu, J; Baker Brachmann, C; Bhargava, P; Wainberg, Z A; Bendell, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 842PCTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Morris, M J; Vogelzang, N J; Sartor, O; Armour, A; Messmann, R; Groaning, M; Robarts, A; Tolcher, A W; Gordon, M; Babiker, H M; Kuo, P; Kearney, M; Jendrisak, A; Wang, Y; Landers, M; Petrylak, D P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-234Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC). (20th June 2018) Authors: Wainberg, Z; Strickler, J; Gordon, M; Barve, M; Wang, L; Yue, H; Motwani, M; Kasichayanula, S; Naumovski, L; Hamilton, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-147Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma. (20th June 2018) Authors: McNulty, M; Dean, A; Das, A; Gordon, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 1603OInitial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. (23rd October 2018) Authors: George, S; Heinrich, M; Chi, P; Razak, A; von Mehren, M; Gordon, M; Ganjoo, K N; Somaiah, N; Trent, J C; Rodon Ahnert, J; Wolf, J; Ruiz-Soto, R; Rosen, O; Janku, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗